OBJECTIVES: To assess race-specific incidence and prevalence rates for systemic lupus erythematosus (SLE) using 1991 National Census data and to ascertain the frequency of clinical/laboratory features of a geographically complete cohort of patients with SLE. METHODS: Multiple methods of retrieval were used to ascertain SLE patients including screening request cards for immunology investigations. Patients were classified according to the revised ARA criteria. Multiple logistic regression analysis was used to study the effects of age at diagnosis on the frequency of clinical/laboratory SLE features. RESULTS: The overall one year period prevalence rate for SLE was 24.7 (age adjusted, 95% CI: 20.7-28.8)/100,000. Highest rates were seen in Afro-Caribbeans (207 (111-302)/100,000), followed by Asians (48.8 (10.5-87.1)/100,000), and then Whites (20.3 (16.6-24.0)/100,000). The mean age at diagnosis of SLE was 40.9 years (range: 11-83) with a mean interval between first definite SLE symptom and diagnosis of 61 months (0-518). In 85% of patients the first definite lupus feature was musculoskeletal and/or cutaneous. In this SLE cohort renal disease (22%) was observed less commonly than in previous studies and the 'classic' butterfly rash was present in only 30% of patients. Malar rash, thrombocytopaenia, positive anti-dsDNA antibodies, hypocomplementaemia (C4), and positive IgG anticardiolipin antibodies were all seen less commonly with increasing age at diagnosis. CONCLUSIONS: A closer estimate of the true frequency of clinical/laboratory SLE manifestations is likely from this geographically complete cohort of patients compared with studies that may be skewed by referral patterns.
OBJECTIVES: To assess race-specific incidence and prevalence rates for systemic lupus erythematosus (SLE) using 1991 National Census data and to ascertain the frequency of clinical/laboratory features of a geographically complete cohort of patients with SLE. METHODS: Multiple methods of retrieval were used to ascertain SLEpatients including screening request cards for immunology investigations. Patients were classified according to the revised ARA criteria. Multiple logistic regression analysis was used to study the effects of age at diagnosis on the frequency of clinical/laboratory SLE features. RESULTS: The overall one year period prevalence rate for SLE was 24.7 (age adjusted, 95% CI: 20.7-28.8)/100,000. Highest rates were seen in Afro-Caribbeans (207 (111-302)/100,000), followed by Asians (48.8 (10.5-87.1)/100,000), and then Whites (20.3 (16.6-24.0)/100,000). The mean age at diagnosis of SLE was 40.9 years (range: 11-83) with a mean interval between first definite SLE symptom and diagnosis of 61 months (0-518). In 85% of patients the first definite lupus feature was musculoskeletal and/or cutaneous. In this SLE cohort renal disease (22%) was observed less commonly than in previous studies and the 'classic' butterfly rash was present in only 30% of patients. Malar rash, thrombocytopaenia, positive anti-dsDNA antibodies, hypocomplementaemia (C4), and positive IgG anticardiolipin antibodies were all seen less commonly with increasing age at diagnosis. CONCLUSIONS: A closer estimate of the true frequency of clinical/laboratory SLE manifestations is likely from this geographically complete cohort of patients compared with studies that may be skewed by referral patterns.
Authors: E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester Journal: Arthritis Rheum Date: 1982-11
Authors: M C Hochberg; R E Boyd; J M Ahearn; F C Arnett; W B Bias; T T Provost; M B Stevens Journal: Medicine (Baltimore) Date: 1985-09 Impact factor: 1.889
Authors: A J Swaak; J C Nossent; W Bronsveld; A van Rooyen; E J Nieuwenhuys; L Theuns; R J Smeenk Journal: Ann Rheum Dis Date: 1989-06 Impact factor: 19.103
Authors: Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold Journal: Arthritis Rheum Date: 2011-04
Authors: Rachel Mackelprang; Robert J Livingston; Michael A Eberle; Christopher S Carlson; Qian Yi; Joshua M Akey; Deborah A Nickerson Journal: Hum Genet Date: 2006-01-20 Impact factor: 4.132
Authors: M Martins; A H Williams; M Comeau; M Marion; J T Ziegler; B I Freedman; J T Merrill; S B Glenn; J A Kelly; K M Sivils; J A James; J M Guthridge; M E Alarcón-Riquelme; S-C Bae; J-H Kim; D Kim; J-M Anaya; S A Boackle; L A Criswell; R P Kimberly; G S Alarcón; E E Brown; L M Vilá; M A Petri; R Ramsey-Goldman; T B Niewold; B P Tsao; G S Gilkeson; D L Kamen; C O Jacob; A M Stevens; P M Gaffney; J B Harley; C D Langefeld; C Fesel Journal: Genes Immun Date: 2015-01-08 Impact factor: 2.676
Authors: R Hal Scofield; Gail R Bruner; Bahram Namjou; Robert P Kimberly; Rosalind Ramsey-Goldman; Michelle Petri; John D Reveille; Graciela S Alarcón; Luis M Vilá; Jeff Reid; Bryan Harris; Shibo Li; Jennifer A Kelly; John B Harley Journal: Arthritis Rheum Date: 2008-08